Both the TAG and G-FINDER report analyze R&D funding according to donors, providing rankings with the top R&D funders for HIV/AIDS and/or TB, respectively. In addition, they depict the allocation of funding according to different fields of research.
The G-FINDER analysis of the latest available data on global R&D funding for HIV/AIDS (Fig. 1) show that currently, by far the biggest share is going into vaccines research (65%), followed by microbicides (18%) and basic research (17%). Only 1% is dedicated to diagnostics research.
With regard to global TB funding, both analyses (G-FINDER, Fig. 2, and TAG, Fig. 3) show the majority of funding going to drugs (35% and 36%, respectively), with 21% and 22% going to vaccines, and 9%/10% supporting diagnostics research. In the G-FINDER report, drug research *Address correspondence to this author at the European Research and Project Office GmbH, Saarbrücken, Germany; Tel: +49 681 95923378; Fax: +49 681 95923370; E-mail: c.giehl@eurice.eu is closely followed by basic research with 32%. This area is sub-divided into basic research and operational research in the TAG report, receiving 20% and 7% respectively. As opposed to the allocation of global funding between different areas of research, the allocation of TB funding in FP6 and FP7 projects (Fig. 4) is clearly focusing on vaccines research, receiving 42% of the total EU funding, followed by basic research (17%), drugs (16%), clinical and epidemiology (13%) and diagnostics (12%) [3] . Fig. (4) . EU FP6/FP7 TB funding.
ONGOING EU PROJECTS
Based on the information available on the website of the infectious diseases unit of the European Commission's Research Directorate for Health [4] , the EC under FP7 is currently funding ten HIV/AIDS projects with an EC contribution of 33.904.935 EUR and fourteen TB projects with a total EC contribution of 37.726.399 EUR. Most projects are dealing with either HIV/AIDS or TB alone; only two of the 24 current projects are explicitly focusing on coinfection issues.
The calculated average monthly funding under FP7 for both diseases has been constantly increasing since the beginning of the framework programme, with average monthly TB funding surpassing monthly AIDS funding in September 2008 (Fig. 5) . As shown in Fig. (6) , Germany, Italy and UK were the countries most actively participating in TB projects. The most frequent EU partner countries involved in HIV/AIDS projects are Italy and France, followed by Germany, UK and Switzerland (all calculations are based on detailed factsheets for all ongoing FP6 and FP7 AIDS and TB projects which can be accessed at the website of the infectious diseases unit of the European Commission's Research Directorate for Health [4] ). 
